Clinical Trial Update: Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the combination of nintedanib and tocilizumab for systemic sclerosis with interstitial lung disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Systemic Sclerosis

Drugs mentioned

• Nintedanib (nintedanib)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | Conditions: Systemic Sclerosis, Interstitial Lung Disease | Phase 3 | Status: RECRUITING